
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co is projected to achieve normalized sales of $156 million in 2026, reflecting a year-over-year growth of 7% due to anticipated market growth and increasing market share in implantable Collamer lenses (ICLs). The company is strategically positioned for expansion with initiatives such as a faster domestic launch of its EVO product and enhanced international adoption, which are expected to drive long-term growth and margin improvement. Additionally, the leadership's focus on streamlining operations and reducing costs is expected to bolster revenue growth and enhance overall profitability.
Bears say
Staar Surgical Co. is facing significant headwinds due to elevated inventory levels with its new distributor in China, leading to a revenue recognition shortfall that adversely impacted 4Q24 results. The company’s bear case scenario suggests that revenue growth may remain flat or decline, exacerbated by potential risks from weak sales and market share losses to lower-cost alternatives. Additionally, broader macroeconomic challenges, coupled with pressures from rising patient out-of-pocket costs and geopolitical risks, further contribute to a negative outlook for Staar Surgical's stock.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares